阿瑞匹坦对妇科恶性肿瘤化疗相关不良反应的影响-肿瘤防治研究.PDF

2018 45 11  Cancer Res Prev Treat,2018,Vol.45,No.11 913 肿瘤防治研究 年第 卷第 期 · · doi:10.3971/j.issn.1000-8578.2018.18.0265 · · 临床应用 阿瑞匹坦对妇科恶性肿瘤化疗相关不良反应 的影响 何杨，杨润峰，周莹莹，徐谦，严浩，蒋蕾，蒋孝会，黄奕 Effect of Aprepitant on Chemotherapy-induced Adverse Reactions in Gynecological Malignancy Patients HE Yang, YANG Runfeng, ZHOU Yingying, XU Qian, YAN Hao, JIANG Lei, JIANG Xiaohui, HUANG Yi Department of Gynecological Oncology, Hubei Cancer Hospital, Wuhan 430079, China Corresponding Author: HUANG Yi, E-mail: huangyt32@ Abstract: Objective To observe the curative effect of aprepitant on chemotherapy-induced nausea and vomiting(CINV) and hemoglobin level in gynecological malignancy patients. Methods A total of 85 gynecological malignancy patients in our hospital from July 2013 to June 2017 were divided into the aprepitant group and the control group, according to patients’ anti-nausea drug usage. Both groups received chemotherapy and conventional symptomatic treatment; the aprepitant group was added with aprepitant. We observed nausea and vomiting, hemoglobin level and peripheral blood in two groups. Results The incidence of nausea and vomiting after chemotherapy was lower in the aprepitant group(P0.05), but there was no significant difference in the incidence of dizziness, headache or other adverse reactions between two groups (P0.05). The decrease of erythrocyte number after chemotherapy in the aprepitant group was slightly less than that in the control group(P0.05). Conclusion The aprepitant could not only effectively prevent the occurrence of chemotherapy-induced nausea and vomiting, improve patients’ quality of life and treatment compliance, but also make patients eat early, which i